Sakhanda Wire
NVDA $154.51 -1.04% MSFT $506.49 -2.22% GOOGL $281.27 -0.86% META $621.51 -0.78% AMZN $256.90 -0.33%
← Back to the news

Anthropic plans biology lab for robot-led drug experiments

Anthropic is establishing a biology laboratory in the San Francisco area to conduct physical experiments and expand its work on AI-assisted drug development beyond computer simulations, according to a report by Reuters. The company plans for its Claude system to direct robots during laboratory procedures, with limited human involvement. Anthropic says people will still oversee the work for safety reasons.

The company has introduced two tools intended to support this approach: Claude Science, an AI workspace for researchers, and the Model Hardware Standard, which is designed to control laboratory equipment. Eric Kauderer-Abrams, who leads Anthropic’s life sciences division, said a major opportunity involves diseases that have often been described as “undruggable” because no treatment is available. He said AI could accelerate the creation of complex antibodies that act on several targets.

The laboratory project follows Anthropic’s acquisition of Coefficient Bio for about $400 million in April and the appointment of Novartis CEO Vas Narasimhan to its board. The company does not currently plan to conduct its own clinical trials, according to the report, in part to avoid competing directly with pharmaceutical companies.

Written by Sakhanda Wire AI from reporting by The Decoder. Facts, quotes and full context are in the original article below.

Originally published by The Decoder on

Read the original on The Decoder ↗

The reporting and the image belong to The Decoder and are credited and linked above; the text on this page is Sakhanda Wire's own summary.

← Back to the news

More stories

All the latest news